Gateway to Indonesia’s Health Security

Delivering sovereign, scalable, and trusted

Biotis Pharmaceuticals Indonesia is Indonesia’s first private human vaccine manufacturer built during the COVID-19 pandemic to serve national health security.

As a gateway to Indonesia’s health security, the organization plays a strategic role in ensuring reliable and sustainable access to essential vaccines. By strengthening local production, expanding scalable manufacturing capacity, and collaborating with global innovators, it helps reduce dependence on imports and supports the continuity of national immunization programs, while contributing to long-term resilience in public health.

Our Purpose

Biotis exists to strengthen health security by expanding access to high-quality vaccines and biologics.
We believe that every country deserves reliable access to essential vaccines and biologics, and every community deserves protection from preventable diseases.

Explore more

Core Strategic Pillars

Our Operational Focus

Four key areas driving our mission to strengthen health security

Strengthening Local Production

Building sustainable vaccine production capacity in Indonesia

Expanding Access

Supporting national immunization and improving availability of essential vaccines and biologics

Global Partnership

Collaboration with international companies for technology transfer and innovation

Research & Innovation

Advancing R&D and quality assurance for safe, effective biologics

Our Journey

Built in Crisis, Proven in the Field

Lorem ipsum dolor, sit amet consectetur adipisicing elit. Voluptas, sint aspernatur ipsa nisi ut, nostrum reprehenderit eveniet beatae animi dolores harum numquam et, ad enim reiciendis voluptatem quae blanditiis neque.

2020

Company incorporated
Research collaboration with Airlangga University to develop COVID-19 vaccine
Participated in the "Vaksin Merah Putih" initiative

2021

Initiated GMP Certification process
Non-clinical trials for the COVID-19 vaccine

2022

Clinical trials for the COVID-19 vaccine
Obtained a complete GMP Certification to produce vaccine
Received Halal Certificate for INAVAC
Receive EUA (Emergency Use Authorization) for INAVAC from Indonesian FDA

2025

Received a permanent marketing license (NIE) for PULMEERA from BPOM
Received a HALAL Certificate for PULMEERA from Halal Product Assurance Body
Signed a partnership and technology transfer agreement with LG Chem for Eupenta
The Ministry of Health of The Republic of Indonesia started to purchase PULMEERA from Biotis

2024

Signed a partnership and technology transfer agreement with Biological E. India
Received marketing license for DPT-Heb-HiB (Penta Valent) vaccine from BPOM
Signed a purchase contract for the Penta Valent Vaccine with the Ministry of Health of the Republic of Indonesia
Signed a MOU with ALPS Global, a Malaysian-based healthcare company, that specializes in stem cell therapy

2023

Launched INAVAC as the first and only human vaccine developed and produced in Indonesia
The ministry of health of the Republic of Indonesia started to purchase INAVAC from Biotis
Received a permanent marketing license for INAVAC from Indonesia FDA
Transfer technology agreement with Beijing Minhai Biotechnology CO., Ltd (Minhai)

Featured Solution

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Laboriosam, odit sint. Incidunt expedita esse consequuntur facilis ipsa animi ipsum, nihil reiciendis aperiam inventore ratione corrupti reprehenderit minus temporibus nesciunt modi.

INAVAC

Lorem ipsum dolor sit amet consectetur adipisicing elit. Dicta officiis voluptate qui obcaecati voluptates, fuga iusto laborum hic esse inventore provident amet quis praesentium consequuntur ratione eius quas! Cupiditate, vel?

ComBE Five

Pulmeera

Strategic Relationship

Kami telah bekerjasama dengan beberapa universitas, pemerintah, dan berbagai entitas bisnis

Latest News

Get updates about our company information

27 November 2025

Participated Biotis on BPOM Expo 2025

Lorem ipsum dolor sit amet consectetur adipisicing elit. Laboriosam debitis reprehenderit possimus? Sit odio nobis asperiores id esse animi exercitationem.

20 October 2025

The Minister of Health officially opens the Biotis vaccine production facility

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Autem ea, iusto sint modi magnam iure amet natus, vero nobis aliquam ipsam, animi repellendus sed quaerat.

15 September 2025

Biotis expands research collaboration with leading universities

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam.

03 August 2025

New vaccine production line achieves international certification

Lorem ipsum dolor sit amet consectetur adipisicing elit. Quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat duis aute irure.

22 July 2025

Biotis receives award for excellence in pharmaceutical innovation

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.

Swipe to explore